Израел - Енглески - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - tablets - atorvastatin as calcium 40 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are prese

Израел - Енглески - Ministry of Health

teva pharmaceutical industries ltd, israel - atorvastatin as calcium - tablets - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - atorvastatin teva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. atorvastatin teva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are prese

Европска Унија - Енглески - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. treatment of paget’s disease of the bone in adults.,

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - imatinib mesilate - film coated tablet - 400 milligram - protein kinase inhibitors

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - imatinib mesilate - film coated tablet - 100 milligram - protein kinase inhibitors

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil - tablets - 32 milligram

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil - tablets - 16 milligram

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil - tablets - 4 milligram

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - candesartan cilexetil - tablets - 8 milligram

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule, hard - excipient ingredients: iron oxide yellow; titanium dioxide; gelatin; sodium lauryl sulfate; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod-teva is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.